High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma

He,Wei‑Peng; Wang,Li‑Li

doi:10.3892/ol.2019.10829

High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma

Authors:
- Wei‑Peng He
- Li‑Li Wang
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510080, P.R. China, State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat‑Sen University, Guangzhou, Guangdong 510060, P.R. China
Published online on: September 9, 2019 https://doi.org/10.3892/ol.2019.10829
Pages: 4900-4906
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The putative oncogenic role of ATP/GTP binding protein like 2 (AGBL2) in catalyzing α‑tubulin detyrosination has recently been characterized in cancer. However, the status of AGBL2 expression in ovarian cancer and its potential clinical and prognostic significance remain unclear. In the present study, immunohistochemistry staining investigated the protein expression level of AGBL2 in paraffin‑embedded pathological specimens from 30 normal ovaries, 35 ovarian cystadenomas, 38 borderline ovarian tumors and 165 invasive ovarian carcinomas. The association between AGBL2 expression and clinicopathological characteristics of patients was evaluated using the χ2 test or Fisher's exact test. The survival status of patients was assessed by receiver‑operator curve analysis. The results demonstrated that high expression of AGBL2 was observed in 9% of cystadenomas cases, 21% of borderline tumors cases and 38% of ovarian carcinomas cases; however AGBL2 expression was not high in normal ovarian tissues (P<0.01). Furthermore, the results demonstrated that high expression of AGBL2 was associated with tumor histological grade, advanced pT/pN/pM and cancer stage according to the International Federation of Gynecology and Obstetrics (P<0.05). Following univariate survival analysis of the ovarian carcinoma groups, high expression of AGBL2 was significantly associated with shorter patient survival (P<0.001). In addition, multivariate analysis revealed that AGBL2 could be identified as a potential independent prognostic factor for overall survival in patients with ovarian carcinoma (P=0.004). Furthermore, the results demonstrated that AGBL2 expression was significantly associated with the expression of immunity related GTPase M (IRGM) (P=0.013) and LC3A/B (P=0.004). IRGM expression level was also significantly associated with LC3A/B expression level (P=0.023). These findings demonstrated that AGBL2 expression was high in ovarian carcinomas, which suggested that AGBL2 may participate in the acquisition of an aggressive phenotype and may therefore serve as an independent prognostic molecular marker.

View Figures

View References

1	Wingo PA, Ries LA, Rosenberg HM, Miller DS and Edwards BK: Cancer incidence and mortality. 1973-1995, a report card for the U.S. Cancer. 82:1197–1207. 1998. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Coburn SB, Bray F, Sherman ME and Trabert B: International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 140:2451–2460. 2017. View Article : Google Scholar : PubMed/NCBI
4	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
5	Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, et al: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol. 16:928–936. 2015. View Article : Google Scholar : PubMed/NCBI
6	Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
7	Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J and Munkarah AR: Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 189:1120–1127. 2003. View Article : Google Scholar : PubMed/NCBI
8	Sahab ZJ, Hall MD, Me Sung Y, Dakshanamurthy S, Ji Y, Kumar D and Byers SW: Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the α-tubulin tyrosination cycle. Cancer Res. 71:1219–1228. 2011. View Article : Google Scholar : PubMed/NCBI
9	de Forges H, Bouissou A and Perez F: Interplay between microtubule dynamics and intracellular organization. Int J Biochem Cell Biol. 44:266–274. 2012. View Article : Google Scholar : PubMed/NCBI
10	Song Y and Brady ST: Post-translational modifications of tubulin: Pathways to functional diversity of microtubules. Trends Cell Biol. 25:125–136. 2015. View Article : Google Scholar : PubMed/NCBI
11	Webster DR, Gundersen GG, Bulinski JC and Borisy GG: Differential turnover of tyrosinated and detyrosinated microtubules. Proc Natl Acad Sci USA. 84:9040–9044. 1987. View Article : Google Scholar : PubMed/NCBI
12	Kato C, Miyazaki K, Nakagawa A, Ohira M, Nakamura Y, Ozaki T, Imai T and Nakagawara A: Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis. Int J Cancer. 112:365–375. 2004. View Article : Google Scholar : PubMed/NCBI
13	Mialhe A, Lafanechère L, Treilleux I, Peloux N, Dumontet C, Brémond A, Panh MH, Payan R, Wehland J, Margolis RL and Job D: Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis. Cancer Res. 61:5024–5027. 2001.PubMed/NCBI
14	Soucek K, Kamaid A, Phung AD, Kubala L, Bulinski JC, Harper RW and Eiserich JP: Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications. Prostate. 66:954–965. 2006. View Article : Google Scholar : PubMed/NCBI
15	Whipple RA, Matrone MA, Cho EH, Balzer EM, Vitolo MI, Yoon JR, Ioffe OB, Tuttle KC, Yang J and Martin SS: Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res. 70:8127–8137. 2010. View Article : Google Scholar : PubMed/NCBI
16	Whipple RA, Balzer EM, Cho EH, Matrone MA, Yoon JR and Martin SS: Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 68:5678–5688. 2008. View Article : Google Scholar : PubMed/NCBI
17	Gundersen GG and Bulinski JC: Selective stabilization of microtubules oriented toward the direction of cell migration. Proc Natl Acad Sci USA. 85:5946–5950. 1988. View Article : Google Scholar : PubMed/NCBI
18	Wang LL, Jin XH, Cai MY, Li HG, Chen JW, Wang FW, Wang CY, Hu WW, Liu F and Xie D: AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma. Cancer Lett. 414:71–80. 2018. View Article : Google Scholar : PubMed/NCBI
19	Zhang H, Ren Y, Pang D and Liu C: Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer. World J Surg Oncol. 12:1422014. View Article : Google Scholar : PubMed/NCBI
20	Yang GF, Li XM and Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer. 19:1342–1346. 2009. View Article : Google Scholar : PubMed/NCBI
21	He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, Guan XY, Xie D and Yang GF: CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer. 12:4372012. View Article : Google Scholar : PubMed/NCBI
22	Xu L, Li X, Cai M, Chen J, Li X, Wu WK, Kang W, Tong J, To KF, Guan XY, et al: Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer. Gut. 65:635–646. 2016. View Article : Google Scholar : PubMed/NCBI
23	Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS and Bast RC Jr: ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ. 21:1275–1289. 2014. View Article : Google Scholar : PubMed/NCBI